Importantly, the phospho-PRASTHR246 epitope was more stable than the phospho-AKTSER473 epitope commonly used for identifying tumours with AKT pathway activation, suggesting that this biomarker might be more suitable for clinical evaluation of PI3K pathway inhibition. The gene discussed is PIK3CD; the disease is neoplasm.